

DETROIT HEALTH DEPARTMENT

UM HMP Opioid Project

Taylor, Mariam, Zakiya, Jordan, Marina

Meeting Agenda

- \rightarrow Project Objectives
- \rightarrow Completed Work to Date
- \rightarrow Issue Tree & Drivers
- \rightarrow Preliminary Findings
- \rightarrow Plan of Action Going Forward
- \rightarrow Preliminary Recommendations
- \rightarrow Questions, Feedback, & Discussion



Project Objectives

Ø

State of Buprenorphine Access



Policy Recommendations



Completed Work to Date

- → Background Research
- → Issue Tree & Driver Diagram
- → Interview Protocol
- → Interviews (12+ completed to date)
 - Contacted Detroit SAMHSA certified Buprenorphine providers
 - Spoke with Michigan Opioid Collaborative to find more interviewees
 - Contacted 30+ local government agencies, FQHCs, addiction experts, PCPs



Preliminary Findings Based on Interviews: Barriers

Provider Perspective

#1: Not identified as a community need
#2: Prior authorization requirements
#3: Stigma (pt. population, risk of diversion)
#4: Cost
#5: Insufficient training

Community Health Center Perspective

#1: Not identified as a community need
#2: Prior authorization requirements
#3: Stigma (risk of diversion) #4: Cost

Preliminary Findings Based on Interviews: Facilitators

Buprenorphine

Cost

Enrollment in 340B Drug DIscount Program and other HRSA grants

Prior Authorization

Waived for many privately insured patients and at certain institutions (VA)

Discussion Forums

I.e. Project ECHO"; multidisciplinary conversations

Relationships with Larger Healthcare Systems

Other Treatment Options

Utilization of other MAT (Naltrexone) and other treatment options



Preliminary Recommendations:

Problem

- \rightarrow Stakeholders: See minimal/no need for Buprenorphine
- → Stakeholders: Unaware of access problems
- → Patients: Not requesting Buprenorphine
- → Legislators: Lack of data & information

Recommendation

- → Share findings with community to facilitate discussion
 - \rightarrow Advocate for elimination of prior authorization



Plans Going Forward

Primary Research	Literature Review	Compile and Code Findings
\rightarrow Complete interviews	→ Review of local laws and guidelines regarding	→ Compile and code responses by respondent
→ Follow up with non-respondents	Buprenorphine	type
	\rightarrow Assess best practices	\rightarrow Focus: barriers,

and innovative solutions from other jurisdictions

facilitators, and solutions







